|Trade names||Retavase, Retefuse, Rapilysin, Mirel, others|
|Drug class||Tissue plasminogen activator|
|Main uses||Heart attacks|
|Side effects||Bleeding, allergic reaction|
|Chemical and physical data|
|Molar mass||39589.75 g·mol−1|
Reteplase, trade names include Retavase, is a thrombolytic medication primarily used to treat heart attacks. It may also be used to treat certain pulmonary embolisms. It is given by injection into a vein.
Common side effects include bleeding. Other side effects may include allergic reactions and cholesterol embolism. Safety in pregnancy is unclear. It is a recombinant protein form of the human tissue plasminogen activator.
It should be used with 12 hours of the start of a heart attack.
Mechanism of action
Reteplase is similar to recombinant human tissue plasminogen activator (alteplase), but the modifications give reteplase a longer half-life of 13–16 minutes. Reteplase also binds fibrin with lower affinity than alteplase, improving its ability to penetrate into clots.
- "Reteplase Monograph for Professionals". Drugs.com. Archived from the original on 15 August 2019. Retrieved 16 October 2021.
- "DailyMed - RETAVASE- reteplase kit". dailymed.nlm.nih.gov. Archived from the original on 17 October 2021. Retrieved 16 October 2021.
- "Reteplase Use During Pregnancy". Drugs.com. Archived from the original on 29 November 2020. Retrieved 16 October 2021.
- "Rapilysin". Archived from the original on 27 April 2021. Retrieved 16 October 2021.
- "Retavase Prices, Coupons & Patient Assistance Programs". Drugs.com. Retrieved 16 October 2021.